One case of severe constipation caused by dapagliflozin

doi:10.19803/j.1672-8629.20240167

Abstract

Abstract: Objective To remind health care professionals to be more alert to the risk of severe constipation associated with dapagliflozin and to provide reference for safe use of this drug. Methods The clinical process of treating a patient who developed severe constipation after taking dapagliflozin tablets was analyzed. Based on related literature, the possible mechanisms and treatment regimens of severe constipation caused by sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were studied. Results One patient developed severe constipation after taking dapagliflozin. After discontinuation of the drug, the patient's constipation improved. However, upon re-administration of dapagliflozin, the patient relapsed into constipation. Immediately after drug withdrawal and treatment with laxatives to moisten the intestines, the patient's conditions improved. The causal relationship of adverse reactions was defined as “definite”, so the severe constipation of this patient was considered to have been caused by dapagliflozin. Conclusion Constipation poses a significant threat to patients' quality of life and may potentially precipitate cardiovascular events. Therefore, it is imperative to enhance clinicians' awareness and pharmacological surveillance regarding the adverse effects of constipation associated with dapagliflozin and SGLT-2i.

Key words: dapagliflozin, constipation, sodium-glucose cotransporter-2 inhibitors (SGLT- 2i), gastrointestinal disorders, drug adverse reaction

CLC Number:

R994.11

LU Jing, YU Shanshan, TONG Fei, LIN Zhuohui, SONG Luyao. One case of severe constipation caused by dapagliflozin[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1071-1074.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240167

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/1071

References

[1] FRĄK W, HAJDYS J, RADZIOCH E, et al. Cardiovascular diseases: therapeutic potential of SGLT-2 Inhibitors[J]. Biomedicines, 2023, 24, 11(7): 2085.
[2] MCMURRAY JJV, DEMETS DL, INZUCCHI SE, et al.A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)[J]. Eur J Heart Fail, 2019, 21(5): 665-675.
[3] WHEELER DC, STEFANSSON BV, JONGS N, et al.Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol, 2021, 9(1): 22-31.
[4] PONIKOWSKI P, SABATINE MS, SOLOMON SD, et al.Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials[J]. Lancet Diabetes Endocrinol, 2022, 10(1): 24-34.
[5] CAI J, WEI J, JI LW.Two cases of euglycemic diabetic ketosis induced by dapagliflozin tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(3): 271-273.
[6] JUNEJA D, NASA P, JAIN R, et al.Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: a meta summary of case reports[J]. World J Diabetes, 2023, 14(8): 1314-1322.
[7] JI L, MA J, LI H, et al.Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study[J]. Clin Ther, 2014, 36(1): 84-100.
[8] GODA M, YAMAKURA T, SASAKI K, et al.Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan[J]. Curr Med Res Opin, 2018, 34(2): 319-327.
[9] YABE D, YASUI A, JI L, et al.Safety and tolerability of empagliflozin in east Asian patients with type 2 diabetes: pooled analysis of phase I-III clinical trials[J]. J Diabetes Investig, 2019, 10(2): 418-428.
[10] Drug Safety Supervision Department of State Food and Drug Administration, National Center for Adverse Drug Reaction. Manual for adverse drug reaction reporting and monitoring(药品不良反应报告和监测手册)[Z]. Beijing, 2012: 49.
[11] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther. 1981, 30(2): 239-245.
[12] Gastrointestinal Dynamics Group, Society of Digestive Diseases, Chinese Medical Association. Colorectal and Anorectal Surgery Group, Surgical Society of Chinese Medical Association. Guidelines for the diagnosis and treatment of chronic constipation in China (Wuhan, 2013)[J]. Chinese Journal of Digestion(中华消化杂志), 2013, 33(5): 291-297.
[13] TURKOSKI BB.“I can’t poop”: medication-induced constipation[J]. Orthop Nurs, 2018, 37(3): 192-196.
[14] Kusunoki M, Hisano F, Matsuda SI, et al.Effects of SGLT2 inhibitors on the intestinal bacterial flora in Japanese patients with type 2 diabetes mellitus[J]. Drug Res (Stuttg), 2023, 73(7): 412-416.
[15] BILLING AM, KIM YC, GULLAKSEN S, et al.Metabolic communication by SGLT2 inhibition[J]. Circulation, 2024, 149(11): 860-884.
[16] REN J, XIAO XH.Rethinking of sodium-glucose cotransporter 2 inhibitor mechanism[J]. Chin J Diabetes Mellitus(中华糖尿病杂志), 2023, 15(7): 656-661.
[17] DOMINGUEZ RIEG JA, RIEG T.What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition[J]. Diabetes Obes Metab, 2019, 21( Suppl 2): 43-52.
[18] JUDKINS CP, WANG Y, JELINIC M, et al.Association of constipation with increased risk of hypertension and cardiovascular events in elderly Australian patients[J]. Sci Rep, 2023, 13(1): 10943.
[19] BASSOTTI G, USAI SATTA P, BELLINI M.Chronic idiopathic constipation in adults: a review on current guidelines and emerging treatment options[J]. Clin Exp Gastroenterol, 2021, 14: 413-428.